Firmenbeschreibung
Die MorphoSys AG ist ein globales, kommerziell ausgerichtetes Biopharma-Unternehmen. MorphoSys vermarktet sein eigenes Medikament Monjuvi in den USA – eine Krebsimmuntherapie in Kombination mit Lenalidomid für die Zweit- und Drittlinien-Behandlung von Patienten mit diffusem großzelligen B-Zell-Lymphom (DLBCL), die nicht für eine Stammzellentherapie in Frage kommen. Tafasitamab wird zudem in einer globalen Studie als mögliche Erstlinientherapie bei DLBCL untersucht. Zwei weitere Produktkandidaten für onkologische Indikationen befinden sich in der späten und mittleren klinischen Entwicklungsphase: Pelabresib, ein selektiver niedermolekularer BET-Inhibitor, wird als potenzielle Behandlungsmöglichkeit für Myelofibrose entwickelt – eine Form von Knochenmarkkrebs mit begrenzten Behandlungsmöglichkeiten; und CPI-0209, ein EZH2-Hemmer der zweiten Generation, der zur Behandlung hämatologischer und solider Tumore untersucht wird. MorphoSys hat seinen Hauptsitz in Planegg bei München und führt sein Geschäft in den USA von Boston, Massachusetts.
KeyData
| endOfFinancialYear: | 31.12.2022 00:00 |
| stockholderStructure: | T. Rowe Price Investment Management, Inc. (5.55%),Logos Global Management LP (1.1%),Opaleye Management Inc. (0.87%),Millennium Management Llc (0.75%),Hudson Bay Capital Management Lp (0.63%),AlphaCentric Advisors LLC (0.14%),Morgan Stanley (0.11%),TD Asset Management, Inc (0.1%),Royal Bank of Canada (0.1%),Optiver Holding B.v. (0.09%) |
| sharesOutstanding: | 34232000.0000 |
| ceo: | Dr. Jean-Paul Kress |
| board: | Lucinda Crabtree, Ph.D., Tim Demuth, M.D., Ph.D., Barbara Krebs-Pohl, Ph.D., Joe Horvat, Maria Castresana, Luisa Ciccarelli |
| supervisoryBoard: | Dr. Marc Cluzel, Dr. George Golumbeski, Krisja Vermeylen, Michael Brosnan, Sharon Curran, Andrew Cheng, M.D., Ph.D. |
| countryID: | 2 |
| freeFloat: | 70.6000 |
| faceValueCurrencyID: | 1 |
| faceValueCurrency: | EUR |
| sectorName: | Biotechnologie |
| industryName: | Biotechnologie |
| subsectorName: | Biotechnologie |
| country: | Deutschland |
| countryName: | Deutschland |
Kontakt
| name: | Dr. Julia Neugebauer |
| phone: | +49 89 89927 179 |
| email: | investors@morphosys.com |
| irWebSite: | https://www.morphosys.com/de/investoren |
Adresse
| street: | Semmelweisstr. 7 |
| city: | D-82152 Martinsried/Planegg |
| phone: | +49-89-89927-0 |
| fax: | +49-89-89927-222 |
| webSite: | www.morphosys.de |
| email: | info@morphosys.de |
Finanzen (kurz)
| year: | 2020 | cash: | 109.8000 |
| balanceSheetTotal: | 1659.5000 | liabilities: | 1038.2000 |
| totalShareholdersEquity: | 621.3000 | sales: | 327.7000 |
| investment: | 92.0000 | incomeBeforeTaxes: | 22.5000 |
| netIncome: | 97.9000 | cashFlow: | 66.2000 |
| employees: | 615 | currencyID: | 1 |
| units: | 1000000 | currency: | EUR |
| year: | 2021 | cash: | 123.2000 |
| balanceSheetTotal: | 2556.3000 | liabilities: | 2311.4000 |
| totalShareholdersEquity: | 244.9000 | sales: | 179.6000 |
| investment: | 96.6000 | incomeBeforeTaxes: | -591.1000 |
| netIncome: | -514.5000 | cashFlow: | 13.5000 |
| employees: | 732 | currencyID: | 1 |
| units: | 1000000 | currency: | EUR |
| year: | 2022 | cash: | 402.4000 |
| balanceSheetTotal: | 2396.9000 | liabilities: | 2239.5000 |
| totalShareholdersEquity: | 157.4000 | sales: | 278.3000 |
| investment: | 412.0000 | incomeBeforeTaxes: | -319.6000 |
| netIncome: | -151.0000 | employees: | 629 |
| currencyID: | 1 | units: | 1000000 |
| currency: | EUR |
Finanzen (kurz)
| year: | 2020 |
| cash: | 109.8000 |
| balanceSheetTotal: | 1659.5000 |
| liabilities: | 1038.2000 |
| totalShareholdersEquity: | 621.3000 |
| sales: | 327.7000 |
| investment: | 92.0000 |
| incomeBeforeTaxes: | 22.5000 |
| netIncome: | 97.9000 |
| cashFlow: | 66.2000 |
| employees: | 615 |
| currencyID: | 1 |
| units: | 1000000 |
| currency: | EUR |
| year: | 2021 |
| cash: | 123.2000 |
| balanceSheetTotal: | 2556.3000 |
| liabilities: | 2311.4000 |
| totalShareholdersEquity: | 244.9000 |
| sales: | 179.6000 |
| investment: | 96.6000 |
| incomeBeforeTaxes: | -591.1000 |
| netIncome: | -514.5000 |
| cashFlow: | 13.5000 |
| employees: | 732 |
| currencyID: | 1 |
| units: | 1000000 |
| currency: | EUR |
| year: | 2022 |
| cash: | 402.4000 |
| balanceSheetTotal: | 2396.9000 |
| liabilities: | 2239.5000 |
| totalShareholdersEquity: | 157.4000 |
| sales: | 278.3000 |
| investment: | 412.0000 |
| incomeBeforeTaxes: | -319.6000 |
| netIncome: | -151.0000 |
| employees: | 629 |
| currencyID: | 1 |
| units: | 1000000 |
| currency: | EUR |
Finanzen (ausführlich)
| year: | 2021 | units: | 1000000 |
| balanceSheetTotal: | 2556.3000 | cash: | 123.2000 |
| currentAssets: | 1133.0000 | liabilities: | 284.5000 |
| nonCurrentLiabilities: | 2026.8000 | totalLiabilitiesEquity: | 2556.3000 |
| provisions: | 26.7000 | totalShareholdersEquity: | 244.9000 |
| employees: | 732 | property: | 7.1000 |
| intangibleAssets: | 880.8000 | longTermInvestments: | 0.0000 |
| inventories: | 20.8000 | accountsReceivable: | 75.9000 |
| currentSecurities: | 16.7000 | accountsPayable: | 188.1000 |
| liabilitiesBanks: | 1681.1000 | liabilitiesTotal: | 2311.4000 |
| longTermDebt: | 1681.1000 | sales: | 179.6000 |
| netIncome: | -514.5000 | operatingResult: | -506.5000 |
| incomeInterest: | -84.9000 | investments: | 455.9000 |
| incomeTaxes: | -76.6000 | materialCosts: | 32.2000 |
| personnelCosts: | 171.1000 | costGoodsSold: | 203.3000 |
| grossProfit: | -23.7000 | revenuePerEmployee: | 245355.1913 |
| cashFlow: | -481.4000 | cashFlowInvesting: | -831.0000 |
| cashFlowFinancing: | 1322.9000 | cashFlowTotal: | 13.5000 |
| equityRatio: | 9.5803 | debtEquityRatio: | 943.8138 |
| liquidityI: | 49.1740 | liquidityII: | 75.8524 |
| netMargin: | -286.4699 | grossMargin: | -13.1960 |
| cashFlowMargin: | -268.0401 | ebitMargin: | -282.0156 |
| ebitdaMargin: | 0.0000 | preTaxROE: | -241.3638 |
| preTaxROA: | -23.1233 | roe: | -210.0857 |
| roa: | -20.1267 | netIncomeGrowth: | -625.5363 |
| revenuesGrowth: | -45.1938 | taxExpenseRate: | 12.9589 |
| equityTurnover: | 0.7334 | epsBasic: | -15.4000 |
| epsDiluted: | -15.4000 | epsBasicGrowth: | -611.6279 |
| shareCapital: | 34.2320 | incomeBeforeTaxes: | -591.1000 |
| priceCashFlowRatio: | -2.3715 | dividendYield: | 0.0000 |
| bookValuePerShare: | 7.1541 | marketCap: | 1141637200.0000 |
| earningsYield: | -46.1769 | cashFlowPerShare: | -14.0629 |
| priceBookValueRatio: | 4.6616 | dividendsPerShare: | 0.0000 |
| netEarningsPerShare: | -15.0298 | currency: | EUR |
| year: | 2022 | units: | 1000000 |
| balanceSheetTotal: | 2396.9000 | cash: | 402.4000 |
| currentAssets: | 1089.0000 | fixedAssets: | 1307.9000 |
| liabilities: | 278.3000 | nonCurrentLiabilities: | 1961.2000 |
| provisions: | 21.2000 | totalShareholdersEquity: | 157.4000 |
| employees: | 629 | property: | 5.9000 |
| intangibleAssets: | 886.6000 | longTermInvestments: | 0.0000 |
| inventories: | 24.3000 | accountsReceivable: | 91.2000 |
| accountsPayable: | 157.3000 | liabilitiesTotal: | 2239.5000 |
| longTermDebt: | 1945.9000 | sales: | 278.3000 |
| netIncome: | -151.0000 | operatingResult: | -220.7000 |
| incomeInterest: | 577.9000 | investments: | 297.8000 |
| incomeTaxes: | 168.6000 | costGoodsSold: | 48.6000 |
| grossProfit: | 229.7000 | cashFlow: | -366.7000 |
| cashFlowInvesting: | 345.0000 | cashFlowFinancing: | 311.4000 |
| accountingStandard: | IFRS | epsBasic: | -4.4200 |
| incomeBeforeTaxes: | -319.6000 | priceCashFlowRatio: | -1.2332 |
| bookValuePerShare: | 4.5980 | marketCap: | 452203967.0300 |
| earningsYield: | -33.4595 | cashFlowPerShare: | -10.7122 |
| priceBookValueRatio: | 2.8730 | netEarningsPerShare: | -4.4111 |
| currency: | EUR |
| year: | 2023 | priceCashFlowRatio: | -2.6138 |
| bookValuePerShare: | 4.5980 | marketCap: | 958494404.0000 |
| earningsYield: | -15.7857 | cashFlowPerShare: | -10.7122 |
| netAssetsPerShare: | 4.5980 | priceBookValueRatio: | 6.0895 |
| netEarningsPerShare: | -4.4111 | currency: | EUR |
Finanzen (ausführlich)
| year: | 2021 |
| units: | 1000000 |
| balanceSheetTotal: | 2556.3000 |
| cash: | 123.2000 |
| currentAssets: | 1133.0000 |
| liabilities: | 284.5000 |
| nonCurrentLiabilities: | 2026.8000 |
| totalLiabilitiesEquity: | 2556.3000 |
| provisions: | 26.7000 |
| totalShareholdersEquity: | 244.9000 |
| employees: | 732 |
| property: | 7.1000 |
| intangibleAssets: | 880.8000 |
| longTermInvestments: | 0.0000 |
| inventories: | 20.8000 |
| accountsReceivable: | 75.9000 |
| currentSecurities: | 16.7000 |
| accountsPayable: | 188.1000 |
| liabilitiesBanks: | 1681.1000 |
| liabilitiesTotal: | 2311.4000 |
| longTermDebt: | 1681.1000 |
| sales: | 179.6000 |
| netIncome: | -514.5000 |
| operatingResult: | -506.5000 |
| incomeInterest: | -84.9000 |
| investments: | 455.9000 |
| incomeTaxes: | -76.6000 |
| materialCosts: | 32.2000 |
| personnelCosts: | 171.1000 |
| costGoodsSold: | 203.3000 |
| grossProfit: | -23.7000 |
| revenuePerEmployee: | 245355.1913 |
| cashFlow: | -481.4000 |
| cashFlowInvesting: | -831.0000 |
| cashFlowFinancing: | 1322.9000 |
| cashFlowTotal: | 13.5000 |
| equityRatio: | 9.5803 |
| debtEquityRatio: | 943.8138 |
| liquidityI: | 49.1740 |
| liquidityII: | 75.8524 |
| netMargin: | -286.4699 |
| grossMargin: | -13.1960 |
| cashFlowMargin: | -268.0401 |
| ebitMargin: | -282.0156 |
| ebitdaMargin: | 0.0000 |
| preTaxROE: | -241.3638 |
| preTaxROA: | -23.1233 |
| roe: | -210.0857 |
| roa: | -20.1267 |
| netIncomeGrowth: | -625.5363 |
| revenuesGrowth: | -45.1938 |
| taxExpenseRate: | 12.9589 |
| equityTurnover: | 0.7334 |
| epsBasic: | -15.4000 |
| epsDiluted: | -15.4000 |
| epsBasicGrowth: | -611.6279 |
| shareCapital: | 34.2320 |
| incomeBeforeTaxes: | -591.1000 |
| priceCashFlowRatio: | -2.3715 |
| dividendYield: | 0.0000 |
| bookValuePerShare: | 7.1541 |
| marketCap: | 1141637200.0000 |
| earningsYield: | -46.1769 |
| cashFlowPerShare: | -14.0629 |
| priceBookValueRatio: | 4.6616 |
| dividendsPerShare: | 0.0000 |
| netEarningsPerShare: | -15.0298 |
| currency: | EUR |
| year: | 2022 |
| units: | 1000000 |
| balanceSheetTotal: | 2396.9000 |
| cash: | 402.4000 |
| currentAssets: | 1089.0000 |
| fixedAssets: | 1307.9000 |
| liabilities: | 278.3000 |
| nonCurrentLiabilities: | 1961.2000 |
| provisions: | 21.2000 |
| totalShareholdersEquity: | 157.4000 |
| employees: | 629 |
| property: | 5.9000 |
| intangibleAssets: | 886.6000 |
| longTermInvestments: | 0.0000 |
| inventories: | 24.3000 |
| accountsReceivable: | 91.2000 |
| accountsPayable: | 157.3000 |
| liabilitiesTotal: | 2239.5000 |
| longTermDebt: | 1945.9000 |
| sales: | 278.3000 |
| netIncome: | -151.0000 |
| operatingResult: | -220.7000 |
| incomeInterest: | 577.9000 |
| investments: | 297.8000 |
| incomeTaxes: | 168.6000 |
| costGoodsSold: | 48.6000 |
| grossProfit: | 229.7000 |
| cashFlow: | -366.7000 |
| cashFlowInvesting: | 345.0000 |
| cashFlowFinancing: | 311.4000 |
| accountingStandard: | IFRS |
| epsBasic: | -4.4200 |
| incomeBeforeTaxes: | -319.6000 |
| priceCashFlowRatio: | -1.2332 |
| bookValuePerShare: | 4.5980 |
| marketCap: | 452203967.0300 |
| earningsYield: | -33.4595 |
| cashFlowPerShare: | -10.7122 |
| priceBookValueRatio: | 2.8730 |
| netEarningsPerShare: | -4.4111 |
| currency: | EUR |
| year: | 2023 |
| priceCashFlowRatio: | -2.6138 |
| bookValuePerShare: | 4.5980 |
| marketCap: | 958494404.0000 |
| earningsYield: | -15.7857 |
| cashFlowPerShare: | -10.7122 |
| netAssetsPerShare: | 4.5980 |
| priceBookValueRatio: | 6.0895 |
| netEarningsPerShare: | -4.4111 |
| currency: | EUR |
